At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 441 enrolled
Drug / intervention
Rimegepantdrug
Likely dose
Rimegepant 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention
In Brief
A Phase 4 clinical trial evaluating Rimegepant for Migraine and 3 related conditions. Completed, enrolled 441 participants across 19 sites.
Detailed Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Episodic Migraine, Phonophobia, Photophobia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartMar 2022
Primary CompletionJul 2024
TodayJul 2026
First PostedJan 26, 2022
Enrollment StartMar 15, 2022
Primary CompletionJul 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.4 years ago
Interventions
Rimegepantdrug
rimegepant ODT 75mg daily